PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDasabuvir
Viekira pak (copackaged), Exviera(dasabuvir)
Exviera, Viekira (dasabuvir) is a small molecule pharmaceutical. Dasabuvir was first approved as Viekira pak (copackaged) on 2014-12-19. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dasabuvir sodium
+
Ombitasvir
+
Paritaprevir
+
Ritonavir
Tradename
Company
Number
Date
Products
VIEKIRA PAK (COPACKAGED)AbbVieN-206619 DISCN2014-12-19
1 products, RLD
VIEKIRA XRAbbVieN-208624 DISCN2016-07-22
1 products, RLD
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hepatitis c—D006526B19.2
acquired immunodeficiency syndromeEFO_0000765D000163B20
chronic hepatitis cEFO_0004220D019698B18.2
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Dasabuvir Sodium / Ombitasvir / Paritaprevir / Ritonavir, Viekira Xr, Abbvie
93332042035-01-02DPU-1889
97441702035-01-02DPU-1889
101053652035-01-02DPU-1889
102015412032-05-17DP
102015842032-05-17U-1889
Dasabuvir Sodium / Ombitasvir / Paritaprevir / Ritonavir, Viekira Pak (Copackaged), Abbvie
96298412033-10-18DPU-1753
102015422033-10-18DPU-1753
84661592032-09-04U-1637
84923862032-09-04U-1840
86801062032-09-04U-1637
86859842032-09-04U-1840
86919382032-04-13DS, DP
86860262031-06-09DP
84205962031-04-10DS, DP
90444802031-04-10U-1638
90063872030-06-10U-1687
86425382029-09-10DS, DPU-1638
81881042029-05-17DS, DPU-1636
85012382028-12-19DS, DPU-1636
91395362028-11-09U-1753
82683492024-08-25DP
83990152024-08-25DP
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AP: Antivirals for treatment of hcv infections
— J05AP09: Dasabuvir
— J05AP52: Dasabuvir, ombitasvir, paritaprevir and ritonavir
HCPCS
No data
Clinical
Clinical Trials
86 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526—B19.2172261852
Chronic hepatitis cD019698EFO_0004220B18.2—72061748
HepatitisD006505—K75.9—72231848
Hepatitis aD006506EFO_0007305B15—72231848
InfectionsD007239EFO_0000544——5161—20
Hiv infectionsD015658EFO_0000764B20—111—2
CoinfectionD060085———111—2
Hepatitis virusesD006518—————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic hepatitisD006521—K73.9—719—1741
Communicable diseasesD003141———510——13
Chronic hepatitis bD019694EFO_0004239B18.1—47——10
FibrosisD005355———26—18
Liver cirrhosisD008103EFO_0001422K74.0—25—17
HepacivirusD016174———14——5
Virus diseasesD014777—B34—14——4
Kidney diseasesD007674EFO_0003086N08——2——2
Acquired immunodeficiency syndromeD000163EFO_0000765B20—11——1
Hepatitis bD006509———11——1
Show 5 more
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HomozygoteD006720——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDasabuvir
INNdasabuvir
Description
Dasabuvir is a member of the class of pyrimidone, which is (as the monohydrate of its sodium salt) in combination with ombitasvir, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. It has a role as an antiviral drug and a nonnucleoside hepatitis C virus polymerase inhibitor. It is a member of naphthalenes, a sulfonamide, an aromatic ether and a pyrimidone. It is functionally related to a uracil.
Classification
Small molecule
Drug classantivirals: RNA polymerase (NS5B) inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C
Identifiers
PDB—
CAS-ID1132935-63-7
RxCUI—
ChEMBL IDCHEMBL3137312
ChEBI ID85182
PubChem CID56640146
DrugBankDB09183
UNII IDDE54EQW8T1 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Viekira – AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,233 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
15,628 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use